Efficacy of Alemtuzumab on disease control in patients with relapse remitting multiple sclerosis who have stopped natalizumab

Trial Profile

Efficacy of Alemtuzumab on disease control in patients with relapse remitting multiple sclerosis who have stopped natalizumab

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Jul 2017

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Jul 2017 New trial record
    • 01 Jun 2017 Preliminary results (n=16) published in the Neurology and Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top